Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01286155 · ClinicalTrials.gov registry record
Epidemiology of Barrett's Esophagus: A Population Based Study
A clinical trial, sponsored by Mayo Clinic.
- Completed
- Registry status
- 534
- Enrollment target
NCT01286155: Completed study, sponsored by Mayo Clinic.
NCT01286155 is a clinical trial that has completed, run by Mayo Clinic. The registered enrollment target is 534 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01286155 has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 534 participants
- Enrollment target
Study Summary
To assess attitudes toward screening for esophageal adenocarcinoma (EAC) and Barrett's esophagus (BE) in the community. To develop a population based clinical risk factor prediction model for the diagnosis of BE and identify novel risk factors for BE which would make population based screening more efficient. This will be an important first step in identifying the target population for BE screening, another crucial component of making screening feasible and efficient
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 534 participants |
| Start Date | 2010-01 |
| Est. Completion | 2011-06 |
What the finished NCT01286155 record still lists
NCT01286155 is an observational study that tracks outcomes without assigning an intervention. The registered 534 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01286155 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01286155 about?
NCT01286155 is a clinical study titled "Epidemiology of Barrett's Esophagus: A Population Based Study". To assess attitudes toward screening for esophageal adenocarcinoma (EAC) and Barrett's esophagus (BE) in the community. To develop a population based clinical risk factor prediction model for the diagnosis of BE and identify novel risk factors for BE which would make population based screening more...
What is the current status of trial NCT01286155?
This trial is currently completed. The enrollment target is 534 participants. The study started on 2010-01. Estimated completion is 2011-06.
Who is sponsoring clinical trial NCT01286155?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04910685 · 534 participants · Phase 2
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
- NCT06128551 · 534 participants · Phase 1
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- NCT05614739 · 535 participants · Phase 1
FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3
- NCT07091617 · 535 participants · NA
Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia